- SID Score
- 7.1/10
- Fair value
- $470.71
- Generated
- Oct 10, 2026
- Model
- claude-haiku-4-5-20251001
UnitedHealth Group is trading at $379.30 with a market capitalization of $305 billion, presenting a moderate buying opportunity with 26.6% upside to the fair value estimate of $470.71. The company demonstrates solid fundamentals with a reasonable P/E ratio of 17.38, though recent earnings have shown mixed performance with beats in April and July but pending results for October. The stock maintains a "Buy" consensus from analysts with an average price target of $387.80, suggesting limited near-term upside but confidence in the healthcare sector positioning. At a dividend yield of 0.03%, this is primarily a capital appreciation play rather than an income investment.
UnitedHealth Group exhibits moderate valuation with a P/E ratio of 17.38, which is reasonable for a diversified healthcare company, though the low dividend yield of 0.03% reflects management's focus on reinvestment and growth rather than shareholder distributions. The SID Score of 7.1/10 indicates solid overall quality, supported by B grades in both Growth and Dividends factors, though profitability receives a concerning C grade suggesting operational challenges or margin compression. Recent quarterly earnings have demonstrated volatility, with significant beats in Q2 (EPS of 7.23 vs. estimate of 6.56, +10.2%) and Q1 (EPS of 6.38 vs. estimate of 4.85, +31.6%), indicating potential operational improvements or one-time gains. The D-rated Value factor suggests the stock may not be deeply discounted, though the fair value estimate of $470.71 provides meaningful upside potential for patient investors.
The stock trades above both its 50-day moving average of $390.02 and 200-day moving average of $350.86, indicating a positive intermediate and long-term trend with approximately 8.3% upside from current price to the 50-day level. The RSI(14) reading of 43.7 suggests the stock is neither overbought nor oversold, positioning it in a neutral zone with room for upward movement before reaching overbought territory above 70. The current price of $379.30 represents a 26.6% discount to the fair value estimate, and sitting between the two moving averages indicates consolidation with potential for a breakout. The technical setup appears constructive, with the stock maintaining support above its 200-day MA and trading in an uptrend relative to that longer-term indicator.
Analyst & Insider Sentiment
The analyst consensus of "Buy" with an average price target of $387.80 suggests modest near-term appreciation of approximately 2.2% from current levels, though this conservative projection may undervalue the stock given the 26.6% upside to fair value. Insider activity on October 1st, 2026 reveals significant buying interest across multiple executives, including Frederick William McNabb III (291 shares), Valerie Montgomery Rice (257 shares), and several others, totaling approximately 1,285 shares purchased by leadership. This coordinated insider buying demonstrates management confidence in the company's prospects and suggests insiders believe the current valuation is attractive, though the transaction dates and magnitudes appear routine. The neutral news sentiment indicates the market has absorbed recent developments without major catalysts, potentially leaving the stock underappreciated.
The primary risk lies in the C-grade profitability rating, which may indicate margin pressures, increased competition in healthcare services, or integration challenges from acquisitions that warrant monitoring in upcoming earnings reports. The pending earnings results for October 2026 represent an immediate risk, as misses on either date could trigger downward price movement and undermine the bullish analyst consensus and insider confidence. Regulatory risks are inherent in healthcare, including potential changes to Medicare/Medicaid reimbursement rates, antitrust scrutiny of large healthcare consolidators, and evolving healthcare policy that could impact revenue streams. Additionally, the low dividend yield combined with analyst price targets showing limited near-term upside suggests limited downside protection, making timing of entry important for risk-adjusted returns.
UnitedHealth Group represents a solid long-term healthcare sector investment for growth-oriented investors seeking exposure to a diversified healthcare operator with reasonable valuation and significant upside potential to $470.71 over a multi-year timeframe. The company's B-rated growth and momentum profiles, combined with coordinated insider buying and analyst consensus support, indicate management and the market expect continued operational improvements and earnings growth despite near-term cautious guidance. The 26.6% fair value upside provides an attractive risk-reward dynamic, particularly for investors with a 2-3 year investment horizon who can weather short-term volatility and pending earnings results. The optimal entry strategy would be to establish positions on any weakness toward the 200-day moving average ($350.86) or following positive earnings beats, with a longer-term price target of $450-475 representing a reasonable exit range.
